Regulatory 2023-02-21 | Ascelia Pharma resolves on conversion of series C shares into ordinary shares for delivery to participants in incentive program PDF Report Presentation Webcast
Regulatory 2023-02-10 | QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023. PDF Report Presentation Webcast
Regulatory 2022-12-06 | New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients PDF Report Presentation Webcast
Regulatory 2022-12-02 | Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2022-11-04 | QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission PDF Report Presentation Webcast
Regulatory 2022-08-18 | Half-year report 2022: Strong results from Orviglance Food Effect Study PDF Report Presentation Webcast
Regulatory 2022-05-11 | Quarterly Report Q1 2022: Strong Orviglance support from healthcare professionals PDF Report Presentation Webcast
Regulatory 2022-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022 PDF Report Presentation Webcast
Regulatory 2022-04-11 | Ascelia Pharma publishes Annual Report for 2021 PDF Report Presentation Webcast
Regulatory 2022-04-05 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB PDF Report Presentation Webcast
Regulatory 2022-03-31 | Number of shares and votes in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2022-03-07 | Ascelia Pharma suspends clinical activities in Russia PDF Report Presentation Webcast
Regulatory 2022-02-10 | Quarterly Report Q4 2021: Strong data for Orviglance vs. a gadolinium contrast agent PDF Report Presentation Webcast
Regulatory 2021-11-30 | Nomination Committee appointed for AGM 2022 in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2021-11-04 | Quarterly Report Q3 2021: Oncoral – entering clinical collaboration PDF Report Presentation Webcast
Regulatory 2021-09-21 | Ascelia Pharma Signs Clinical Collaboration Agreement With Taiho Oncology, Inc. for the Development of Oncoral in Combination with LONSURF® PDF Report Presentation Webcast
Regulatory 2021-08-19 | Quarterly Report Q2 2021: Preparing Oncoral for the next level PDF Report Presentation Webcast
Regulatory 2021-08-18 | Covid-19 extends recruitment period of SPARKLE study PDF Report Presentation Webcast
